56882-41-8

Usage

InChI:InChI=1/C17H15FN2O/c18-14-7-5-13(6-8-14)17(21)11-12-3-1-2-4-15(12)16-19-9-10-20(16)17/h1-8,21H,9-11H2

Upstream product

• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 403-33-8 methyl 4-flurobenzoate 
• 57327-93-2 2-(o-Tolyl)-2-imidazoline 

Relevant academic research and scientific papers

5-HETERO-OR ARYL-SUBSTITUTED-IMIDAZO(2,1-A)ISOQUINOLINES AND THEIR USE AS PAF RECEPTOR ANTAGONISTS

The invention discloses certain 5-hetero or aryl-substituted-imidazo[2, 1-a]isoquinolines useful as platelet activating factor (PAF) receptor antagonists, pharmaceutical compositions containing said compounds as an active ingredient thereof and a method of using such compositions for inhibiting PAF-mediated bronchoconstriction and extravassation and PAF-mediated, endotoxin-induced lung injury, and for controlling hyperreactive airways induced by PAF or allergin. In addition, the invention discloses the use of a select group of said compounds as anti-tumor agents.

Antidepressant activity of 5-aryl-2,3,5,6-tetrahydroimidazo[2,1-a]isoquinolin-5-ols

A series of 5-aryl-2,3,5,6-tetrahydroimidazo[2,1-a]isoquinolin-5-ols was prepared and evaluated for potential antidepressant activity in the reserpine-induced hypothermia model and selected central nervous system and autonomic activity tests. Several members of the series, notably the 4-chloro- and 4-fluorophenyl analogues, demonstrated pharmacological activity in the range of imipramine. Both compounds provided a marked potentiation of the 5-hydroxytryptophan-facilitated monosynaptic spike in the spinal cat preparation.